Biotech China 2014

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase1/2 kinase Clinical Cancer Research Apr 14 2009 Epub
2. 2009 Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Molecular Cancer Therapeutics 8(6): 1589-95
3. 2009 A novel analytic approach to the prediction of respiratory diaphragm motion based on external torso volume change Phys. Med. Biol. 54(13):4113-30
4. 2009 Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clinical Cancer Research Jun 23
5. 2009 Tofilon, PJ: Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro Molecular Cancer Research 7: 489-97
6. 2009 In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clinical Cancer Research 15(2): 607-12
7. 2009 Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis Cell Cycle 8(13): 2093-100
8. 2009 Introduction. Seminar Introduction. Seminar in Radiation Oncology 19(3):141
9. 2009 Molecular Targets for Tumor Radiosensitization. Chemical Reviews Apr 2 Epub
10. 2009 Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters. Radiation research 171: 236-244
11. 2008 Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments . Journal of Applied Clinical Medical Physics 9(4), 2781
12. 2008 Neuropsychological testing and biomarkers in the management of brain metastases Radiation Oncology 3:26
13. 2008 Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clinical Cancer Research 14(17): 5410-5
14. 2008 Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis and Review 27(3): 415-34
15. 2008 Advancement of antiangiogenic and vascular disrupting agents combined with radiation Cancer Treat Res 139:153-71
16. 2008 Principles of radiation oncology Cancer Management: a multidisciplinary approach. 11th Edition
17. 2008 Advances in 4D medical imaging and 4D radiation therapy Technol Cancer Res Treat. 7(1):67-82
18. 2008 Quantitative method to study the network formation of endothelial cells in response to tumor angiogenic factor. Clin Can Res 14(3): 931-8
19. 2008 Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects . Cancer Immunol Immunother 57(8): 1173-83
20. 2008 Post-collection, pre-measuremnt variablesaffecting VEGF levels in urine biospecimens. Cell Mol Med. 12(1):343-50
21. 2008 Radiation-induced gene translation profiles reveal tumor type and cancer-specific components Cancer Research 68(10):3819-26
22. 2008 Clinical Cancer Research Clinical Cancer Research 14(13): 4241-9
23. 2008 Safety and immunological response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clincal Cancer Research 14(16): 5284-91
24. 2008 Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations JCO 26(24): 3987-94
25. 2008 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Journal of Clinical Oncology
26. 2008 Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens. J Cell Mol Med 12(4): 1250-55
27. 2007 Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by epic score Int J Radiat Oncol Biol Phys 70(1): 90-5
28. 2007 Topology of the heterogeneous nature of the extracellular matrix on stochastic modeling of tumor-induced angiogenesis. Microvascular Research Nov 22
29. 2007 Evaluation of novel agents as radiosensitizers from laboratory to clinic. ASCO Educational Book 705-708
30. 2007 Inhibition of HSP90: a multitarget approach to radiosensitization. Clinical Cancer Research 13: 4326-30
31. 2007 Inhibition of histone deacetylation: a strategy for tumor radiosensitization Journal of Clinical Oncology 25: 4051-
32. 2007 Synergistic antitumor activity of immune strategies combined with radiation. Frontiers in Bioscience 12:4900-10
33. 2007 Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study Radiation Oncology 2:19
34. 2007 The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology Cancer 111(3): 173-84
35. 2007 Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 110(1): 441-9
36. 2006 An endogenous inhibitor of endothelial cell growth from transitional cell carcinoma clipped β2-glycoprotein-I. Annals of Surgical Oncology 13(9): 1241-51
37. 2006 Combining radiotherapy and angiogenesis inhibitors: clinical trial design International Journal of Radiation Oncology, Biology and Physics 64(1): 15-25
38. 2006 Why Radiation Oncology Radiat Oncol 1(1): 1
39. 2006 Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism Journal of the National cancer Institute 98(22): 1634-46
40. 2006 Inhibition of Hsp90 compromises the DNA damage response to radiation. . Cancer Research 66(18):9211-20
41. 2006 Early Observed Transient Prostate-Specific Antigen Elevations On a Pilot Study of External Beam Radiation Therapy and Fractionated MRI Guided High Dose Rate Brachytherapy Boost Radiation Oncology August 16;1:28
42. 2006 Clinical relevance of maspin expression in bladder cancer World Journal of Urology 24(3): 338-44
43. 2006 Enhancement of anti-tumor activity against mesothelin expressing tumor xenografts using the combination of tumor directed radiation and the immunotoxin SS1P. Clinical Cancer Research 12(16): 4983-8
44. 2006 A pilot trial of a carcinoembryonic antigen/TRICOM-based vaccine and radiation to liver metastasis in patients with carcinoembryonic antigen-positive solid tumors Clin Colorectal Cancer 6(1): 72-5
45. 2006 Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther. 5(6): 1504-10
46. 2006 Radiation modultes the peptide repertoire of MHC class I molecules and induces successful anti-tumor immunotherapy. J Exp Med 203(5): 1259-71
47. 2006 Intrarectal Amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. Int J Radiat Oncol Biol Phys 65(4): 1008-13,
48. 2006 A dosimetric analysis of dose escalation using two intensity modulated radiation therapy techniques in locally advanced, unresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 65(1): 274-83
49. 2006 Radiation-induced changes in gene expression involve recruitment of existing mRNAs to and away from polysomes. Cancer Research 66(2): 1052-61
50. 2006 Discovering clinical biomarkers of ionizing radiation exposure with serum proeomic analysis Cancer Research 66(3): 1844-50
51. 2006 Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T MRI scanner . Journal of Urology 175(1): 113-20
52. 2006 Intra and inter-therapist reproducibility of daily isocenter verification using prostatic fiducial markers. Radiat Oncol 1(1): 2
53. 2006 Anti-angiogenic and anti-tumor effects of Bevacizumab in inflammatory and locally advanced breast cancer patients Journal of Clinical Oncology 24: 769-777
54. 2005 ErbB3 expression predicts tumor cell radiosensitization induced by HSP90 inhibition Cancer Research 65(15): 6967-75
55. 2005 Implications for tumor control during protection of normal tissues with antioxidants Journal of Clinical Oncology 23(24): 5455-7
56. 2005 Combining angiogenesis inhibitors with radiation. 7th ICDTF. Mehta, M., Paliwal, B., and Bentzen, S. Medical Physics Publishing. Pages 16-30
57. 2005 Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. International Journal of Cancer 114(3): 380-6
58. 2005 Inverse Treatment Planning Based on MRI for HDR Prostate Brachytherapy. International Journal of Radiation Oncology Biology and Physics 61(4): 1267-75
59. 2005 An interventional MRI technique for the molecular characterization of intra-prostatic dynamic contrast enhancement Molecular Imaging 4(1): 63-66
60. 2005 Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. International Journal of Radiation Oncology Biology and Physics 62(5): 1316-21
61. 2005 Early ipsilateral breast tumor recurrences after breast conservation affects survival: an analysis of the NCI randomized trial International Journal of Radiation Oncology Biology and Physics 62(3): 785-9
62. 2005 Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clinical Cancer Research 11(9): 3353-3362
63. 2005 Volumetric voxel image registration: development for multi-modality image fusion International Journal of Radiation Oncology Biology and Physics 63(1): 261-73
64. 2005 Quantitative method to study the network formation of endothelial cells in response to tumor angiogenic factor. IEE Proceedings Systems Biology 152(2): 61-66
65. 2005 Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clinical Cancer Research 11(12): 4571-9
66. 2005 Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proceeding of the National Academy of Sciences 102(23): 8287-92
67. 2005 The requirement of multimodality therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors Clinical Cancer Research 11(12): 4533-44
68. 2005 Inhibition of NF-kB and target genes during combined therapy with proteasome inhibitor Bortezomib and re-irradiation in patients with recurrent head and neck squamous cell carcinoma. International Journal of Radiation Oncology Biology and Physics 63(5): 1400-1412
69. 2005 Orthotopic growth of human glioma cells increases their susceptibility to radiation-induced modifications in gene expression. Cancer Research 65(22): 10389-93
70. 2004 Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy International Journal of Radiation Oncology Biology and Physics 58(5): 1536-39
71. 2004 In vivo tumor imaging utilizing a near-infrared labeled Endostatin molecule International Journal of Radiation Oncology Biology and Physics 58(2): 536-541
72. 2004 Three-color labeling method for flow cytometric analysis of cytogenetic damge in rodent and human blood. Environmental Molecular Mutagenesis 44(5): 427-35
73. 2004 Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor DMAG (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin). Clinical Cancer Research 10(23): 8077-84
74. 2004 Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clinical Cancer Research 10(18): 6066-71
75. 2004 Microarray analysis in clinical oncology: pre-clinical optimization using needle core biopsies from xenograft tumors BMC Cancer 4(1): 20
76. 2004 MRI-Guided HDR Prostate Brachytherapy in a Standard 1.5T Scanner International Journal of Radiation Oncology Biology and Physics 59(5): 1414-23
77. 2004 System for prostate brachytherapy and biopsy in a standard 1.5T MRI scanner Magnetic Resonance Medicine 52(3): 683-7
78. 2004 External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research 62(12): 4328-4337
79. 2004 Evaluation of chelating agents as anti-angiogenic therapy through copper chelation Bioorganic Medicinal Chemistry 12(19): 5133-40
80. 2004 In vivo tumor imaging in mice with near infrared labeled Endostatin. Molecular Cancer Therapeutics 3(4): 481-488
81. 2004 Effect of angiogenesis inhibitors on cyclophosphamide induced bladder inflammation in mice Angiogenesis 7(1): 69-73
82. 2004 Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gH2AX foci Molecular Cancer Therapeutics 3(4): 409-416
83. 2004 Predictive significance of urinary vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) levels and trends in patients with cancer . Journal of Clinical Oncology 22(3): 499-506
84. 2004 Combining radiation and molecular targeting in cancer therapy Cancer Biology and Therapy, 3(3): 247-50
85. 2004 Murine in vivo imaging and its role in preclinical modeling of novel agents Expert review of Anticancer Therapy, 4(5): 857-864,
86. 2004 The combination of angiogenesis inhibitors and radiotherapy for the treatment of primary tumors. In: Pharmacokinetics and pharmacodymanics of anti-cancer drugs. Eds: William Figg and Howard McLeod. Humana Press Totowa, NJ. Pages 431-438
87. 2004 The present and future of molecularly targeted therapy, Chapter in “Clinical Oncology Editors. Elsevier Churchill and Livingstone. Pages 623-638
88. 2004 Microarray analysis of gliosarcoma tissue. Check Sample Clinical Chemistry 44(5): 51-63
89. 2004 Enhanced cell killing induced by the combination of radiation and the histone deacetylase inhibitor MS-275. Cancer Research 64: 316-21
90. 2003 Development of investigational radiation modifiers. Journal of the National Cancer Institute 95(9): 646-651
91. 2003 Enhanced cell killing induced by the combination of radiation and the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multi-target approach to radiosensitization. Clinical Cancer Research 9:3749-3755
92. 2003 Vascular Endothelial Growth Factor effect upon angiogenesis and hypercoagulopathy in glioblastoma multiforme and other conditions. Check Sample. Clinical Chemistry 43
93. 2003 Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Research 63: 7377-7383
94. 2003 Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results Seminars In Oncology 30(6): 62-66
95. 2003 Angiogenic tumor markers, anti-angiogenic agents and radiation therapy. Expert Review of Anti-cancer therapy 3(3): 357-
96. 2003 Irradiation of tumor cells upregulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy Journal of Immunology 170: 6338-47
97. 2003 Evaluation of copper chelation agents as anti-angiogenic therapy. Bioorganic and Medicinal Chemistry 11(19): 4287-93
98. 2003 A mathematical approach to the antiangiogenic hypothesis. Bulletin of Mathematical Biology 65: 407-424
99. 2003 Radiation abscopal anti-tumor effect is mediated through p53. Cancer Research April 15; 63: 1990-1993
100. 2002 Angiogenesis inhibitors and radiotherapy of primary tumors. Expert Opinion on Biological Therapy. 2(5); 477-481
101. 2002 Combination therapy with anti-angiogenic agents and radiotherapy European Journal of Cancer, 13 (13 Suppl.),
102. 2002 Tumor hypoxia: chicken, egg or a piece of the farm? Journal of Clinical Oncology, Feb 1: 20(3): 610-615
103. 2002 A portrait of an editorial board member Cell Cycle. 1(5); 296-297
104. 2001 Low dose ionizing irradiation for the inhibition of posterior capsule opacification. International Journal of Radiation Oncology and Physics 49(3): 817-25
105. 2001 Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Research 61(5): 2207-11
106. 2001 What does radiotherapy do to the endothelial cells? Science 293: 114-116
107. 2001 In vivo gene expression profile analysis of early diabetic retinopathy. Investigational Ophthalmology and Visual Sciences, Nov 1; 42(12): 3047-3057
108. 1995 TCR alpha and beta CDR3 expression by myelin basic protein specific human T cell clones Acad. Sci 756: 317-318
109. 1995 Diversity of T-cell receptor V-alpha, V-beta and CDR3 gene utilization in the human response to myelin basic protein. Neurology 45: 1919-1922
110. 1994 HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2MBP, in multiple sclerosis. J. Immunology 153: 4834-4844

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.